Elicio Therapeutics (ELTX) Total Non-Current Liabilities (2021 - 2026)

Elicio Therapeutics (ELTX) has 6 years of Total Non-Current Liabilities data on file, last reported at $20.5 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities rose 26.1% year-over-year to $20.5 million; the trailing twelve-month figure through Mar 2026 stood at $20.5 million (up 26.1% YoY), and the FY2025 full-year result was $21.6 million, down 41.05% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $20.5 million, down from $21.6 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $36.7 million in Q4 2024 and bottomed at $11.0 million in Q2 2022.
• The 5-year median for Total Non-Current Liabilities is $18.4 million (2025), against an average of $20.2 million.
• The widest annual swing landed in 2024, when Total Non-Current Liabilities soared 132.6%; it then slumped 41.05% in 2025.
• A 5-year view of Total Non-Current Liabilities shows it stood at $11.0 million in 2022, then soared by 43.66% to $15.8 million in 2023, then jumped by 132.6% to $36.7 million in 2024, then plunged by 41.05% to $21.6 million in 2025, then retreated by 5.02% to $20.5 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $20.5 million (Q1 2026), $21.6 million (Q4 2025), and $20.6 million (Q3 2025), per Business Quant data.

Peer Comparison